News Releases

Date Title and Summary Additional Formats
September 18, 2020 Ayala Pharmaceuticals Presents Positive Interim Data from Phase 2 ACCURACY Trial of AL101 for the treatment of Recurrent/Metastatic Adenoid Cystic Carcinoma with Notch Activating Mutations at ESMO 2020
– Interim data showed meaningful clinical activity of AL101 4mg monotherapy with deep responses and 68% disease control rate -  Company to host virtual KOL event to review data today at 8:00am ET REHOVOT, Israel and WILMINGTON, Del., Sept. 18, 2020 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc.
September 14, 2020 Ayala Pharmaceuticals to Host Virtual KOL Event Reviewing Interim Data Presented at ESMO 2020 from Ongoing Phase 2 ACCURACY Trial of AL101 for the Treatment of Recurrent/Metastatic Adenoid Cystic Carcinoma
REHOVOT, Israel and WILMINGTON, Del., Sept. 14, 2020 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in
September 8, 2020 Ayala Pharmaceuticals to Present at Upcoming Investor Conferences
REHOVOT, Israel and WILMINGTON, Del., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in
August 20, 2020 Ayala Pharmaceuticals Announces the Appointment of Vered Bisker-Leib, Ph.D. To Its Board of Directors
REHOVOT, Israel and WILMINGTON, Del., Aug. 20, 2020 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (Nasdaq: AYLA) (the Company or Ayala), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers,
August 13, 2020 Ayala Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Business Update
REHOVOT, Israel and WILMINGTON, Del., Aug. 13, 2020 – New interim data from Phase 2 ACCURACY study of AL101 for the treatment of R/M ACC to be presented at ESMO 2020 – – On track to initiate patient dosing in Phase 2 TENACITY study of AL101 for the treatment of TNBC in 2020 –
July 27, 2020 Ayala Pharmaceuticals to Present Updated Data from Ongoing Phase 2 ACCURACY Trial of AL101 for the Treatment of R/M Adenoid Cystic Carcinoma at the European Society for Medical Oncology (ESMO) Virtual Congress 2020
REHOVOT, Israel and WILMINGTON, Del., July 27, 2020 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in
June 22, 2020 Ayala Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Business Update
– Completed upsized initial public offering raising a total of $59.1 million in gross proceeds – Current cash balance expected to fund operations into second half of 2022 – Fast Track Designation granted for lead candidate, AL101 for the treatment of R/M ACC; additional Phase 2 data expected in
June 1, 2020 Ayala Pharmaceuticals to Present at Upcoming Investor Conferences
REHOVOT, Israel and WILMINGTON, Del., June 01, 2020 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in
May 12, 2020 Ayala Pharmaceuticals Announces Closing of Initial Public Offering
REHOVOT, Israel & WILMINGTON, Del., May 12, 2020 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically
May 7, 2020 Ayala Pharmaceuticals Announces Pricing of Initial Public Offering
REHOVOT, Israel and WILMINGTON, Del., May 07, 2020 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in
Displaying 1 - 10 of 11